TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05884281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 0.5 mg once daily for treatment period
Study: NCT04921852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: costoclavicular brachial plexus block
Description: A transverse scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed immediately below the midpoint of the clavicle and over the medial infraclavicular fossa. 20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected in to the middle of the three brachial plexus cords with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance .Readiness for surgery time will be evaluated after costoclavicular block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral sagittal infraclavicular block
Description: A sagittal scan with an portable USG machine with a high-frequency linear array transducer ((Logiq E, General Electric, ABD) will be performed medial to the coracoid process to obtain a transverse view of the axillary artery.20 ml of a mixture of 0.25% bupivacaine, 1% lidocaine will be injected posterior to the axillary artery near to the three cords of brachial plexus with an echogenic SonoTAP(Pajunk GmbH Medizintechnologie, Geisingen, Germany) block needle under USG guidance.Readiness for surgery time will be evaluated after lateral sagittal infraclavicular block.
Study: NCT05976659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS); Transcranial alternating current stimulation (tACS)
Description: Transcranial electrical stimulation (tES), via direct and alternating current, will be administered to the participants in their home by trained caregivers/study companions administrators. All training and intervention sessions will take place in the participant's home.
Study: NCT06568549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF) Maintenance Group
Description: Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Maintenance in Immunosuppression medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF) Withdrawal Group
Description: Mycophenolate Mofetil (MMF), administered orally as standard of care post kidney transplant as part of their immunosuppression regimen. Withdrawal of MMF immunosuppression medication.
Study: NCT05884281

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for treatment period
Study: NCT05176951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Palmitil
Description: Oral inhalation using a capsule-based dry powder inhaler device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral inhalation using a capsule-based dry powder inhaler device.
Study: NCT05019651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Wearable System
Description: Participants will be provided with the Apollo wearable device and asked to install the study mobile application on their mobile phone. Participants will use the Apollo for at least 30 minutes after waking up in the morning and at least 30 minutes before bed on the corresponding settings for those times of day. They will be given the Apollo Device TVS (10-200 Hz) to borrow which they will be instructed to wear for 6 +/- 2 weeks. They will be asked to continue to wear the device until all study data is collected.
Study: NCT04749563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IGC AD1
Description: IGC AD1 oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of IGC AD1 oral Solution
Study: NCT05439551

Intervention type: DIAGNOSTIC_TEST
Intervention: MeMed BV®
Description: Patients Serum and Whole blood samples will be examined using the MeMed BV® test. Test results will have no impact on patient management.
Study: NCT04941469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Specifically optimized off-the-counter foot orthosis (Medical grade foot orthosis)
Description: The study device is a specifically optimized off-the-counter foot orthosis modified by an additional wedging added onto the original Formthotics (Original Dual Hard) with standard arch fill reduction to achieve a foot orthosis that is tailored for the management of mechanical foot pains in the Subtle Cavus foot type. The original Formthotics (Original Dual Hard) is currently in use and is considered a Class A medical device according to the Health Science Authority of Singapore risk classification system. At the moment, the original Formthotics (Original Dual Hard) is also available in the retail market, abeit, without assessment guided optimisations for specific feet types.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plain off-the-counter foot orthosis (Medical grade foot orthosis)
Description: The control device for this study would be the plain original Formthotics (Original Dual Hard).
Study: NCT06224907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Valoctocogene roxaparvovec
Description: Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A
Study: NCT05793957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-Based Intervention
Description: Use smartphone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Technology Intervention
Description: Use VR headset
Study: NCT06403293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment (AH Plus-NA)
Description: Root canal treatment procedures explained in arm descriptions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment (AH Plus-EA)
Description: Root canal treatment procedures explained in arm descriptions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment (BC-NA)
Description: Root canal treatment procedures explained in arm descriptions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal treatment (BC-EA)
Description: Root canal treatment procedures explained in arm descriptions.
Study: NCT05759546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Parp inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalpiciclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant/AI
Description: Endocrine therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant/AI
Description: Endocrine therapy
Study: NCT05610722

Intervention type: DEVICE
Group type: OTHER
Intervention: DreaMed Endo Digital
Description: The DreaMed Endo.Digital uses information gathered from glucose monitoring (sensor readings or capillary blood glucose measurements), insulin dosing and meal data during daily routine home care. Following a 5-minute data collection and analysis, the algorithm learns and suggests insulin dose adjustments and behavioral tips for optimization of glucose control. The algorithm is designed as an advisory tool for health care professionals.
Study: NCT04853589

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel
Description: After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 1 will receive hyaluronic acid gel.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel + carrier
Description: After the local anesthesia is injected, alveolar curettage is performed, and the socket is rinsed with saline solution. Prior to wound closure, patients from the test group 2 will receive hyaluronic acid gel together with a collagen carrier.
Study: NCT05291572

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: speech therapy only
Description: fluency shaping technique

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: speech therapy only
Description: fluency shaping technique

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: speech therapy only
Description: fluency shaping technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric oxygen therapy
Description: chamber system using oxygen with pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical treatment
Description: brain stimulant
Study: NCT05277116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genome Informed Risk Assessment (GIRA) report
Description: A Genome Informed Risk Assessment (GIRA) report that combines genetic (monogenic risks and polygenic risk scores), family history, and clinical risk information from participants.
Study: NCT05352165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Other individualized treatments
Description: Other individualized treatments based on organoids drug sensitivity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other individualized treatments
Description: Other individualized treatments based on organoids drug sensitivity
Study: NCT06281327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding.~Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count \>250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L.
Study: NCT05070871

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydrolyzed Collagen
Description: Hydrolyzed collagen type II derived from the bone powder of Norwegian Atlantic salmon.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pure maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CalGo
Description: CalGo is a natural marine collagenic bone powder from salmon. The bone powder is a 100 % microcrystalline hydroxyapatite form of calcium and collagen type 2.
Study: NCT05579275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCXH-212 Injection
Description: Based on the development principle of NCV, a community-type tumor neoantigen mRNA vaccine, JCXH-212 injection, has been developed that can be applied to patients with malignant solid tumors. NCVs activate tumor-specific CD4+ T cells and CD8+ T cells through active immunity, and these T cells can inhibit and kill tumor cells in cancer patients, thus prolonging the survival of cancer patients.
Study: NCT04749472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sling
Description: Participants wore six different shoulder slings in a randomized order.
Study: NCT05406063

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: Stereotactic multiple fraction radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic multiple fraction radiotherapy
Study: NCT05960513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Exercises followed by Meditation
Description: Breathing exercises and Meditation taught by Prasanna Wellness, a non-profit organization, helps dissolve stress and create a proper system in the mind. These breathing exercises include slow deep breaths and rapid breaths and are followed by meditation. Meditation is a guided meditation that helps to eliminate stress and establish an apposite system in the mind, therefore inducing physiological and mental relaxation whilst the eyes are shut. The proposed duration and frequency of the follow-up will be 60-minutes weekly for 11 weeks.
Study: NCT06119425

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood-based CRC screening
Description: For this study, a commercially available blood-based CRC screening test will be used. The selected test is Shield (Guardant Health, Redwood City, California, USA). The Shield test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, California, USA, which is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing. The Shield test is currently commercially available as an laboratory developed test (LDT). Additionally, Guardant submitted the pre-market approval (PMA) application for the Shield test to the Food and Drug Administration (FDA) in March of 2023. Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of medical devices. To this end, the Shield test is currently under review by the FDA.
Study: NCT05412212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LTBI video intervention
Description: 3-minute educational video about latent tuberculosis and importance of taking and completing treatment
Study: NCT06438965

Intervention type: DEVICE
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: MSOT scans will be obtained from two muscle region to measure hemo/myoglobin, collagen and lipid content/signal and oxygenation in patient with neuromuscular diseases.
Study: NCT05953324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kiwifruit
Description: 2 kiwifruit for 6 weeks
Study: NCT06107036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching BI 101550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching BI 101550
Study: NCT06468111

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal Assisted Therapy
Description: Blood and dental extraction will be performed according to the usual protocol of the health center in both groups; with the additional assistance of the therapy dog in experimental group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy
Description: Blood and dental extraction will be performed according to the usual protocol of the health center in both groups; with the additional assistance of the therapy dog in experimental group.
Study: NCT05856669

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality gaming
Description: This study aims to combine the motivational delivery of therapy which is an immersive virtual reality with the foundational concepts of mirror therapy. By utilizing a recalibration software, the participant will be able to achieve magnified movements on their screen as compared to the limited movement that is occurring in reality. The recalibration software takes each plane of movement of the gaming controller and magnifies the participant's range of motion in order to promote greater participation and success in the game that they are playing (Walkin VR). By using the fundamental concepts of mirror therapy in an immersive virtual reality setting, the investigators aim to mimic the results of mirror therapy while increasing motivation and adherence to the therapeutic program to increase overall upper extremity function.
Study: NCT05200429

Intervention type: DRUG
Intervention: Trikafta
Description: Highly Effective CFTR Modulator Therapy
Study: NCT06106243

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The conventional heat pressing temporary flexible maxillary removable partial denture
Description: An intraoral scan will be made for each patient's maxillary and mandibular jaws in addition to digital bite registration using (Medit i700; Medit corp.) the resultant data will be exported in the form of a Standard Tessellation Language (STL) file. The denture base and the teeth will be designed using computer-aided design software (Partial Cad, Dental CAD software). Each patient will receive two RDPs, fabricated with two different manufacturing techniques. Based on randomization, the patients will start by receiving either partial denture that is fabricated by conventional heat pressing technique of 3D printed castable resin (Cast V1resin) followed by partial denture that is fabricated by 3D printing of printable resin (Flexo denture base, resin) and teeth (permanent crown,resin) or the other way around. In 3D-printed RDP, the artificial teeth will be attached to the fabricated denture bases using printable denture base resin material

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D-printed and digitally designed temporary flexible maxillary removable partial denture
Description: 3D-printed and digitally designed temporary flexible maxillary removable partial denture
Study: NCT04969432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Client-centered
Description: Rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Client-centered
Description: Rehabilitation
Study: NCT04616495

Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Chemotherapy and liver transplantation
Study: NCT04789863

Intervention type: DEVICE
Group type: OTHER
Intervention: SMILe-Integrated Care Model
Description: Four self-management intervention modules will be delivered by human and technology: 1) monitoring \& follow-up; 2) infection prevention; 3) medication adherence; 4) physical activity.~Human. A CC will provide structured and tailored self-management and behavioural support regarding all 4 modules via 12 face-to-face meetings congruent with planned clinic follow-up visits. The CC will be connected with the patients via the SMILe technology, enabling rapid responses to early signs of health deterioration.~Technology. The SMILe technology consists of the SMILeApp and SMILeCare. The latter is the interface of the monitoring component to connect the patient with the CC supporting fast recognition of symptoms and health deterioration. The SMILeApp enables to daily record a set of medical, behavioural and symptom-related data. A lexicon provides self-management and behavioural information. All data will be transferred to the clinic to be monitored, with the patient's consent, via SMILeCare.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The control group (CG) participants will receive usual care, which includes no specific counselling. USB outpatient appointment frequency follows a standard schedule: during the first 3 months post-alloSCT, depending on their health status, most patients (73%) return 1 to 3 times per week for follow-up at the USB outpatient clinic, where they are mainly seen by a junior or senior physician. Depending on health status and recovery, follow-up intervals extend to weekly or monthly within 1 year post-alloSCT. A research assistant (RA) will just contact CG participants for data collection. If participants raise concerns about any symptoms, the RA will encourage them to contact their physicians.
Study: NCT05721781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral Hygiene instruction
Description: Participants will be instructed on the Modified Bass technique for toothbrushing: brushing with a soft bristled toothbrush held at a 45 degree angle to the gums and brushed in a circular motion. Participants will also be instructed to floss at least once per day using floss or another inter-dental device (e.g., floss pick).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Cleaning
Description: Participants will receive a dental cleaning according to the current standard of care for routine dental cleanings.
Study: NCT05112484

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic testing
Description: One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic testing
Description: One blood tube will be taken for genetic testing for the duration of the study, again with standard and routine single injections before taking the drug.
Study: NCT03460769

Intervention type: OTHER
Intervention: Data Management and Monitoring
Description: The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).

Intervention type: OTHER
Intervention: Data Management and Monitoring
Description: The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).

Intervention type: OTHER
Intervention: Data Management and Monitoring
Description: The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for the coordination and data management for the Evaluation of a mixed meal test for Diagnosis and characterization of Type 3c diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis (DETECT), which is part of the NIH U01 funded Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC).
Study: NCT04808466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).